share_log

Gevo Analyst Ratings

Benzinga Analyst Ratings ·  Dec 14, 2022 04:52
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
12/14/2022 12.5% UBS → $2.25 Initiates Coverage On → Neutral
10/19/2022 15% Jefferies → $2.3 Initiates Coverage On → Hold
08/24/2021 400% Stifel → $10 Initiates Coverage On → Buy
02/19/2021 800% HC Wainwright & Co. $5 → $18 Maintains Buy
07/13/2020 150% HC Wainwright & Co. $10 → $5 Maintains Buy
02/06/2020 50% Noble Capital Markets → $3 Initiates Coverage On → Outperform
09/07/2018 400% HC Wainwright & Co. → $10 Upgrades Neutral → Buy
01/09/2018 HC Wainwright & Co. Downgrades Buy → Neutral

What is the target price for Gevo (GEVO)?

The latest price target for Gevo (NASDAQ: GEVO) was reported by UBS on December 14, 2022. The analyst firm set a price target for $2.25 expecting GEVO to rise to within 12 months (a possible 12.50% upside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Gevo (GEVO)?

The latest analyst rating for Gevo (NASDAQ: GEVO) was provided by UBS, and Gevo initiated their neutral rating.

When is the next analyst rating going to be posted or updated for Gevo (GEVO)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gevo, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gevo was filed on December 14, 2022 so you should expect the next rating to be made available sometime around December 14, 2023.

Is the Analyst Rating Gevo (GEVO) correct?

While ratings are subjective and will change, the latest Gevo (GEVO) rating was a initiated with a price target of $0.00 to $2.25. The current price Gevo (GEVO) is trading at is $2.00, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment